PURA Gears Up To Enter Marijuana Pharmaceutical Market Competing With Likes of GWPH MJNA and CBIS
August 04 2017 - 11:47AM
InvestorsHub NewsWire
Austin, TX -- August 04, 2017 -- InvestorsHub
NewsWire -- Wolf Wrangler
We’ve got our eyes on Puration, Inc.
(USOTC:
PURA) and expect to see an announcement coming soon on the
Company’s entry into the marijuana pharmaceutical
market.d
PURA is a highly innovative company
with a laser-beam focus on becoming the number one cannabis extract
company in the market. The Company operates a U.S. Patented
Cannabis Extraction process for the recreational market
today. Without many food and beverage companies out there yet
looking for cannabis extracts to infuse into consumer products,
PURA is partnering to help create there first customers. PURA
has been instrumental in the development of the EVERx Cannabis
Infused Sports and Fitness Nutritional Supplements consumer product
line, in addition to helping to Create Spanish Peaks Cannabis
Infused Products, and AmeriCanna Cafe Cannabis Infused
Products. It appears the Company now has its sights set on
entering the Marijuana Pharmaceutical sector.
The Company just announced the acquisition of a 25 greenhouse grow
operation in Texas were the first medical marijuana licenses are to
be issued next month. In a presentation on the Company’s website on
the strategic plan for the acquisition, it did not slip by us that
the Company makes mention of angling to enter the marijuana
pharmaceutical market combining their patented cannabis extraction
process with the development of their own cannabis strains.
Existing university partnerships have already indicated that the
extracts coming from the patented extraction process compare
favorably to the extracts from GW Pharmaceuticals (GWPH).
An announcement clarifying specific plans to enter the market
alongside GWPH and others such as Medical Marijuana (MJNA)
and Cannabis Science (CBIS)
could bring new attention to PURA making others see the laser-beam
focus and innovation that we believe sets this company apart from
other cannabis sector competitors.
The Company’s online strategic presentation also highlights a $1.2
million contract signed in conjunction with the 25 greenhouse grow
operation, and the potential to rapidly grow revenue from the
acquisition to $16 million in annual sales with a longer-term
potential to see revenue exceed $100 million in annual
sales.
See the recent PURA shareholder presentation on the strategy to
grow its recently acquired 25-greenhouse grow operation highlighted
in the MMJ Observer Article:
Puration’s Grow Operation Business
Strategy Overview
The Wolves of
Wall Street are hard at work cornering their prey –
retail investors. We’re not looking to beat the wolves. We’re
looking to pickup their trial and run with the pack as our own
breed of hunter. We’re Wolf
Wranglers, recognizing the unchangeable predatory
nature of the Wolf and directing it for our own
benefit. If you’re looking to make big returns on small
investments as can only be realized on the micro cap public market,
then this is the site for you. Sign-up to
share your own opportunity yet undiscovered by the market and to
learn from others about opportunities not yet discovered by the
market.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2023 to Mar 2024